Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Total Valuation
Avalo Therapeutics has a market cap or net worth of $43.31M. The enterprise value is ―.
Market Cap$43.31M
Enterprise Value―
Share Statistics
Avalo Therapeutics has 10,827,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,827,620
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Avalo Therapeutics’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -47.62%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-47.62%
Return on Capital Employed (ROCE)-0.48
Revenue Per Employee19.17K
Profits Per Employee-1.53M
Employee Count23
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avalo Therapeutics is -1.72. Avalo Therapeutics’s PEG ratio is -0.04.
PE Ratio-1.72
PS Ratio0.00
PB Ratio0.52
Price to Fair Value0.45
Price to FCF-1.84
Price to Operating Cash Flow-1.40
PEG Ratio-0.04
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 441.00K and earned -35.13M in profits. Earnings per share was -4.32.
Revenue441.00K
Gross Profit-26.83M
Operating Income-68.51M
Pretax Income-35.02M
Net Income-35.13M
EBITDA-68.51M
Earnings Per Share (EPS)-4.32
Cash Flow
In the last 12 months, operating cash flow was -49.06M and capital expenditures 0.00, giving a free cash flow of -49.06M billion.
Operating Cash Flow-49.06M
Free Cash Flow-49.06M
Free Cash Flow per Share-4.53
Dividends & Yields
Avalo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change-64.87%
50-Day Moving Average5.71
200-Day Moving Average8.41
Relative Strength Index (RSI)33.21
Average Volume (3m)62.67K
Important Dates
Avalo Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Avalo Therapeutics as a current ratio of 19.96, with Debt / Equity ratio of 0.43%
Current Ratio19.96
Quick Ratio19.96
Debt to Market Cap0.00
Net Debt to EBITDA1.96
Interest Coverage Ratio-20.65
Taxes
In the past 12 months, Avalo Therapeutics has paid 114.00K in taxes.
Income Tax114.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Avalo Therapeutics EV to EBITDA ratio is 1.07, with an EV/FCF ratio of 1.50.
EV to Sales-166.86
EV to EBITDA1.07
EV to Free Cash Flow1.50
EV to Operating Cash Flow1.50
Balance Sheet
Avalo Therapeutics has $134.55M in cash and marketable securities with $568.00K in debt, giving a net cash position of -$133.98M billion.
Cash & Marketable Securities$134.55M
Total Debt$568.00K
Net Cash-$133.98M
Net Cash Per Share-$12.37
Tangible Book Value Per Share$15.07
Margins
Gross margin is 174.83%, with operating margin of -15535.60%, and net profit margin of -7965.76%.
Gross Margin174.83%
Operating Margin-15535.60%
Pretax Margin-7939.91%
Net Profit Margin-7965.76%
EBITDA Margin-15535.60%
EBIT Margin-7187.76%
Analyst Forecast
The average price target for Avalo Therapeutics is $36.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$36.40
Price Target Upside860.42% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-69.59%
EPS Growth Forecast―